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Abstract
Adenosine exerts a spectrum of energy preserving actions on the heart including negative 
chronotropic effects. The pathways leading to adenosine formation have remained 
controversial. In particular, although cytosolic 5’nucleotidases can catalyse adenosine 
formation in cardiomyocytes their contribution to the actions of adenosine has not been 
documented previously.  We recently cloned two closely related AMP preferring cytosolic 
5’nucleotidases (cN-IA and B); the A form predominates in heart. In this study we 
overexpressed pigeon cN-IA in neonatal rat cardiomyocytes using an adenovirus.  cN-IA 
overexpression increased adenosine formation and release into the medium caused by 
simulated hypoxia and by isoproterenol in the absence and presence of inhibitors of 
adenosine metabolism. Adenosine release was not affected by an ecto-5’-nucleotidase 
inhibitor, α,β-methyleneADP but was by the nucleoside transporter, dipyridamole. The 
positive chronotropic effect of isoproterenol (130±3 vs 100±4 beats/ min) was inhibited 
(107±3 vs 94±3 beats/ min) in cells overexpressing cN-IA and this was reversed by addition 
of adenosine receptor antagonist, 8-(p-sulfophenyl)theophilline (120±3 vs 90±4 beats/ min). 
Our results demonstrate that overexpressed cN-IA can be sufficiently active in 
cardiomyocytes to generate physiologically effective concentrations of adenosine at its 
receptors.
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Introduction
Adenosine exerts a spectrum of actions on the heart that include increasing coronary 
blood flow (2, 31), antagonizing the effects of catecholamines both pre- and post synaptically 
(18, 32) and prolonging atrioventricular conduction time (16). These actions are brought 
about by a family of cell surface adenosine receptors that have been extensively characterized 
(34). All the actions of adenosine on the heart tend to increase energy supply or reduce 
energy demand. Moreover, there appears to be a direct link between energy utilization and 
the rate of adenosine formation, which suggest that adenosine functions physiologically as a 
cardioprotective metabolite (23). The role of adenosine in ischaemic preconditioning (22)
may also be an extension of this concept. 
An ecto-5’nucleotidase (e-N) can catalyse the terminal dephosphorylation of AMP to 
adenosine. Biochemical experiments with inhibitors, and cloning, demonstrated conclusively 
that this enzyme is only capable of metabolizing extracellular nucleotides, in a cascade with 
other ecto-enzymes (39). Consistent with this, adenosine derived from AMP perfused through 
the heart requires e-N (25).  However, a link between intracellular energy utilization, 
nucleotide release and e-N activity is at best controversial. In neonatal myocytes, adenosine 
formation induced by chemical hypoxia occurs exclusively intracellularly (21), although the 
extracellular pathway may also contribute in adult myocytes (4). The situation in the whole 
heart is more complicated due to the contribution made by the vasculature and nerve 
terminals. Experimental evidence has been presented in favour (13, 15) and against (3, 33)
the involvement of the ecto-pathway under normoxic and hypoxic conditions. Deussen and 
colleagues (7) used trapping of adenosine through S-adenosylhomocysteine hydrolase and 
mathematical modelling to estimate the contribution of cytosolic and extracellular pathways 
to adenosine production in normoxic guinea-pig hearts.  They concluded that 8 to 11% of 
adenosine production derived from extracellular metabolism. However, increased adenosine 
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formation in hearts stimulated by catecholamines (8, 9) apparently does not involve e-N (3, 
19).
Alternatively, adenosine could be formed from cytosolic AMP, which rises during 
ATP breakdown owing to the myokinase equilibrium, by the action of a cytosolic 
5’nucleotidase (cN). Adenosine might then be released from cells via equilibrative nucleoside 
transporters (17). An IMP-preferring enzyme, cN-II, was cloned and overexpressed and 
shown to selectively catalyse conversion of IMP to inosine rather than AMP to adenosine 
(28). An AMP-preferring enzyme was originally cloned from pigeon (30) and then from man 
and mouse (14, 29).  When overexpressed, this enzyme selectively catalyzed conversion of 
AMP to adenosine.  Furthermore, selective inhibitors of cN-I inhibit adenosine formation 
from rat adult myocytes under chemical hypoxia (11).  Interestingly two cN-I genes were 
identified; cN-IA, the form originally purified and cloned from pigeon, is abundantly 
expressed in pigeon and human heart (14, 30).  cN-IB is abundant in the testis, where it was 
also cloned as human autoimmune infertility related antigen (Genbank AF356185). Doubts 
remain regarding the role of cN-I in the myocardial actions of adenosine, in particular 
because its Km for AMP measured in the test tube is around 5 mM, much higher than 
predicted cytosolic AMP concentrations. In addition most previous studies of cN-I activity 
have used inhibitors of adenosine kinase and adenosine deaminase to prevent further 
metabolism. While these studies provide absolute rates of adenosine formation, they leave 
unanswered the question whether sufficient adenosine can escape metabolism so as to carry 
out physiological effects at extracellular receptors. In the present studies, we overexpressed 
pigeon cN-IA in rat cardiomyocytes using adenovirus mediated gene transfer. We then 
studied adenosine formation under simulated hypoxia with and, importantly, without 
inhibitors of adenosine metabolism. Finally we investigated the influence of cN-IA 
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overexpression on a physiological response, namely beating rate in cardiomyocytes 
stimulated with isoproterenol. 
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Material and Methods
Materials. Tissue culture products were from Invitrogen. Molecular biology reagents, 
nucleotides and nucleosides and the cell cytotoxicity test (LDH measurement) were from 
Roche Biochemicals. Reagents for Western blotting were from Amersham and those for 
immunocytochemistry from DAKO. General laboratory reagents and chemicals were 
obtained from Sigma.
Construction of a recombinant adenoviral vector. The coding sequence of pigeon cN-
IA was excised with BamHI and KpnI, and subcloned into the shuttle vector pDC 515 
downstream the mouse CMV promoter (Microbix Biosystems Inc.Canada). Replication-
deficient adenovirus was generated by site-specific FLP mediated recombination of the 
cotransfected shuttle and genomic plasmids in 293 cells. Viral stocks were plaque purified, 
amplified, CsCl banded and titrated according to the manufacture’s instructions.
Culture and infection of rat neonatal cardiomyocytes. Myocytes  were isolated from 
2-3 day-old rats by 4 cycles of digestion in 0.1% trypsin containing 0.02% EDTA in PBS. 
Digestion was stopped by addition of FCS to 20%. The dispersed cells were resuspended in 
MEM supplemented with 10% FCS, 100 µg/ml streptomycin, 100 U/ml penicillin and pre-
plated for 1 hour to allow fibroblasts to adhere. The suspended myocytes were seeded on 
plates previously coated with 1 % gelatin in PBS for 1h. 106 myocytes were seeded in 35mm 
dishes for beating rate measurements or 5x105 on 12-well plates for metabolite assays. After 
40 hours in culture more than 80% of the cells were beating spontaneously. The culture 
medium was then changed to 4:1 DMEM: M199 containing antibiotics and 1% FCS and 
adenoviral infection was performed. A previously described adenovirus expressing β-
galactosidase (37) was used to control for the non-specific effects of viral infection. 
Metabolic studies. Cells in 12 well dishes were washed in saline, transferred to KRH 
(containing in mM: NaCl, 120; KCl, 4.8; KH2PO4, 1.2; MgSO4, 1.2; CaCl2, 1.3; HEPES, 25; 
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pH 7.3) and preincubated for 10 minutes at 37°C. Metabolic inhibition was triggered with 10 
mM 2-deoxyglucose (DOG), 10 mM DOG plus 1 mM sodium dithionite (S2O4) or 10 mM 
DOG plus 0.5 mM sodium cyanide (CN). Control cells were incubated in control buffer 
(KRH containing 5.5 mM glucose and 1 mM sodium pyruvate). Adenosine formation caused 
by β-adrenergic stimulation with 20 µM isoproterenol was measured in control buffer. In 
order to inhibit adenosine metabolism 10 µM erythro-9-(2-hydroxy-3nonyl)adenine (EHNA), 
an inhibitor of adenosine deaminase (EC 3.5.4.4) (24) and 50 µM 5’-amino-5’-
deoxyadenosine (5’NH2) to inhibit adenosine kinase (EC 2.7.1.20) (24) were included in 
some experiments. The nucleoside transport inhibitor dipyridamole was added at a final 
concentration of 10µM from a 10mM solution in DMSO. Cell incubations were terminated 
by the addition of 0.75 volumes of 1.6M HClO4 and total purines and protein concentrations 
determined by HPLC as previously described (30). Separate experiments were conducted to 
measure adenosine in the medium by HPLC. To stop incubations, 300µl of the supernatant 
buffer were removed and frozen immediately. After carefully removing the rest of the buffer, 
400µl of 1.2M HClO4 were added to assay purines and protein in the cell pellet as described 
above. Cell viability was assessed by measurement of LDH in cell supernatants at the end of 
the incubations and expressed as a percentage of the total LDH present in parallel wells 
extracted in KRH containing 0.1% TritonX-100.
Activities of purine metabolizing enzymes. Cell extracts were prepared in buffer containing in 
mM: Na dimethylglutarate, 20; Na β-glycerophosphate, 20; KCl, 100; DTT, 0.1; 0.1% 
TritonX-100 and a Sigma protease inhibitory cocktail (P8340), pH 6.9 . Assays for cytosolic 
5’nucleotidase were performed in extraction buffer with near-saturating substrate 
concentrations (10mM AMP) in the presence of the activator ADP (1 mM), the selective e-N 
inhibitor, α,β-methyleneADP (50 µM), an inhibitor of adenosine deaminase, pentostatin 
(2µM) and 5’-amino-5’-deoxyadenosine (10µM), (30).  e-N was assayed in buffer containing 
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in mM: Tris-HCl, 50; Na β-glycerophosphate, 10; MgCl2 , 5 and 0.1% tritonX-100, pH 8.0 
containing 0.2mM AMP as substrate in the presence of an inhibitor of adenosine deaminase, 
pentostatin (2µM) and the adenosine kinase inhibitor 5’-amino-5’-deoxyadenosine (10µM). 
AMP deaminase was assayed in buffer containing in mM: Na dimethylglutarate, 20, EDTA, 
1; DTT, 0.1 and KCl, 150, pH 7.0 containing 15mM AMP as substrate and 1.5mM ATP as 
activator. Adenosine deaminase was measured in 50mM potassium phosphate buffer pH 7.4 
containing 150µM adenosine. Aliquots of extracts containing 10-20µg of protein were 
incubated for between 0 and 10 min at 37 °C, the reactions were stopped by addition of 
HClO4 followed by analysis of the products by HPLC as already described (30). Adenosine 
kinase was measured at 37 °C in aliquots containing 1.5-3µg of protein using 14C adenosine 
as substrate (5).  
Effects of cN-IA overexpression on beating rates. Cells 35mm dishes were transferred 
to HEPES buffered RPMI1640 (0.8ml). Beating rates were determined by counting the beats 
of four groups of cells for 1min using a heated microscope stage maintained at 37°C. 
Determinations were made after equilibrating for 10 min under all conditions used.
Western blots and immunocytochemistry. The generation of the rabbit polyclonal 
antibody against peptides derived from the sequence of pigeon cN-IA and the methods used 
for western blotting have been described previously (30).
Statistical analysis. Results are expressed as mean±SEM. Statistical significance was 
assessed with one-way analysis of variance (ANOVA) followed by paired Student’s t-test if 
appropriate or unpaired Student’s t-test with Bonferroni correction for repeated measures. A 
value of p<0.05 was considered significant.
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Results
Adenovirus-mediated overexpression of cN-IA in rat cardiomyocytes
Infection of neonatal rat cardiomyocytes with a multiplicity of infection of 10 plaque 
forming units (pfu) per cell of an adenovirus that drives β-galactosidase expression 
transduced more than 90% of cells (Fig. 1A). Infection with a similar virus engineered to 
express pigeon cN-IA led to overexpression of a protein of the correct size by western 
blotting using a previously described antibody against a peptide epitope in pigeon cN-IA 
(Fig. 1B). This was accompanied by an 18-fold increase in 5’-nucleotidase activity from 
45±6 to 824±36 nmol.min-1.mg protein-1 (n=7). By immunocytochemistry using the same 
antibody as for western blotting more than 90% of cardiomyocytes in cN-IA-adenovirus-
infected cultures stained for cN-IA (Fig 1D). The activity (nmol.min-1.mg protein-1) of other 
purine metabolizing enzymes was similar in β-galactosidase and cN-IA transduced cells as 
follows: eN 134±16 versus 142±4; adenosine kinase 3.9±0.9 versus 3.8±1.0; adenosine 
deaminase 12.5±1.7 versus 12.1±1.4 and AMP deaminase 125±29 versus 119±26.
Effect of cN-IA overexpression on nucleotide metabolism under simulated hypoxia
Purine concentrations were measured in cardiomyocytes plus medium after incubation 
under increasingly severe conditions of metabolic poisoning to simulate the effects of 
hypoxia either in the presence or absence of inhibitors of adenosine kinase (5’NH2) and 
adenosine deaminase (EHNA) (24). As shown in Table 1, 2-deoxyglucose (DOG), a 
glycolytic inhibitor, alone decreased ATP concentrations by approximately 40%. This was 
increased to approximately 55% by adding dithionite (S2O4) that consumes molecular 
oxygen, and to approximately 70% by adding cyanide, an inhibitor of cytochrome oxidase 
(Table 1). Transduction with β-galactosidase had no effect on baseline ATP concentration or 
ATP catabolism compared to untransduced cells (results not shown). The baseline ATP 
concentration was decreased significantly by 8% in cN-IA transduced cardiomyocytes (43±3 
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nmol/mg protein, n=7) compared to β-galactosidase transduced cells (47±2 nmol/mg protein, 
n=7, p<0.02). Despite this, there was no difference in the percentage of ATP broken down 
between β-galactosidase and cN-IA transduced cells under any condition of chemical hypoxia 
(Table 1). Including inhibitors of adenosine metabolism did not affect either the baseline ATP 
concentration in β-galactosidase or cN-IA transduced cells (48±3 and 44±3 nmol ATP/mg 
protein, respectively, n=3, p=NS) or the percentage ATP breakdown during chemical hypoxia 
(Table 1). Cardiomyocyte viability measured by lactate dehydrogenase (LDH) release was 
>98% in both β-galactosidase and cN-IA transduced cells. Only in cN-IA transduced cells 
treated with DOG and cyanide was LDH marginally elevated (Table 1).
Transduction with cN-IA profoundly altered the pattern of ATP metabolites produced 
either in the presence or absence of inhibitors of adenosine metabolism (Fig 2A, B). These 
figures summarize the pattern of nucleotide metabolism in representative experiments. 
Overexpression of cN-IA increased adenosine production (Fig. 2A, B), even in the absence of 
inhibitors of adenosine metabolism (Fig. 2A). cN-IA overexpression increased adenosine 
production at the expense of IMP, inosine and hypoxanthine, as most clearly seen in the 
presence of inhibitors of adenosine metabolism (Fig. 2B). This demonstrates competition
between cN-IA and AMP deaminase for the available cytosolic AMP. Only with DOG and 
cyanide, when ATP is most depleted, did AMP accumulate in β-galactosidase transduced 
cells (Fig 2A, B). This is probably due to the inhibition of AMP deaminase known to occur 
under such conditions (20). With DOG and cyanide, cN-IA overexpression reduced the final 
AMP concentration. Averaged data from several experiments (Fig. 3A, B) demonstrates that 
even under base line conditions, cN-IA overexpression significantly increased the 
concentration of adenosine in the presence or absence of inhibitors of adenosine metabolism 
(Fig 3A, B). Moreover, cN-IA overexpression dramatically potentiated the stimulatory effects 
of simulated hypoxia on adenosine concentration (Fig. 3A, B). The patterns of changes after 
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simulated hypoxia were similar in the absence of inhibitors of adenosine metabolism, 
although the absolute levels of adenosine achieved were approximately halved (Fig. 3A, B). 
As expected, there was correspondingly more inosine and hypoxanthine in the absence of 
inhibitors of adenosine metabolism than in their presence (Fig. 2A, B).  In agreement with 
our previous work in rat neonatal cardiomyocytes (21), inclusion of the selective e-N 
inhibitor, AOPCP (50 µM) did not affect adenosine formation under any condition of 
simulated hypoxia (data not shown and see below).
We conducted a separate set of experiments in which medium and cells were analysed 
separately. Values for adenosine concentration in the medium (Fig. 4) were similar to those 
measured in cells plus medium in Fig. 3B, which shows that most of the adenosine was 
present in the medium, as we previously reported (21). Medium adenosine concentrations 
were not affected by inclusion of AOPCP either under baseline or after treatment with DOG 
and cyanide. However the nucleoside transport inhibitor, dipyridamole, dramatically reduced 
medium adenosine concentrations. Adenosine concentrations in the cells were below the 
limits of accurate measurement, except in the case of DOG plus cyanide plus dipyridamole, 
when they were 4-fold the extracellular concentration. Conversely, ATP, ADP or AMP 
concentrations were not measurable by HPLC in the medium under any condition (data not 
shown). These data confirm our previous study (21), which showed that the overwhelming 
majority of adenosine is formed intracellularly in neonatal rat cardiomyocytes, independently 
of e-N, and then transported out. Not surprisingly, overexpression of cN-IA increased 
intracellular adenosine formation.
Effect of cN-IA overexpression on nucleotide metabolism and beating frequency after 
stimulation with isoproterenol
The increase in total (cells plus medium) adenosine concentration resulting from 
overexpression of cN-IA persisted in the presence of 20µM isoproterenol whether or not 
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inhibitors of adenosine metabolism were also present (Fig. 5A).  In a separate series of 
experiments we measured adenosine concentration in the medium alone. Medium adenosine 
concentrations were also significantly greater in cN-IA than β-galactosidase transduced cells 
and this difference again persisted in the presence of isoproterenol (Fig. 5B). The difference 
between cN-IA and β-galactosidase transduced cells was preserved in the presence of 
AOPCP but lost in the presence of dipyridamole (Fig. 5B). These data confirm that cN-IA 
overexpression led to an increase in adenosine formation and release, which was present both 
before and after isoproterenol treatment.  
Isoproterenol significantly and reversibly increased the beating frequency of 
cardiomyocytes transduced with β-galactosidase (Fig. 6A). The effect of isoproterenol was 
not reversed by including inhibitors of adenosine metabolism but was by adding 50 µM 
adenosine, which had no effect on beating frequency in the absence of isoproterenol (Fig. 4A 
and data not shown). By contrast, isoproterenol did not increase beating frequency in 
cardiomyocytes overexpressing cN-IA (Fig. 6A). To confirm that these effects were mediated 
through adenosine receptors, the experiments were repeated in the presence of a nonselective 
adenosine receptor antagonist, 8-sulphophenyltheophylline (8-SPT). 8-SPT had no effect on 
the ability of isoproterenol to stimulate beating frequency but partially antagonized the 
inhibition of this by added adenosine (Fig. 6B). More importantly, however, 8-SPT
completely abolished the inhibitory effect of cN-IA overexpression on isoproterenol induced 
beating frequency (Fig. 6B).
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Discussion
Cytosolic 5’nucleotidases were first characterized and named based on kinetic and 
physical properties during purification from avian, rodent and human hearts.  The so-called 
cN-II, was the first to be cloned from chicken and man (26). It is a tetramer of 60 kDa 
subunits and prefers IMP (Km ~ 0.2mM) over AMP (Km ~ 5 mM). It is activated in vitro by 
ATP or ADP and inhibited by inorganic phosphate, which implies a biphasic response during 
ATP breakdown that has been confirmed in whole cell experiments (38). The so-called cN-I 
was later cloned from pigeon, man and mouse (14, 29, 30). Although cN-I and II may share 
similar catalytic residues (1), they are genetically unrelated.  The purified enzyme is a 
tetramer of 40 kDa subunits that has a preference for AMP (Km ~ 5 mM) compared to IMP 
(Km ~ 20 mM). It is insensitive to inorganic phosphate and requires a nucleoside diphosphate 
(e.g. ADP) for maximum activity (nucleoside triphosphates cannot act as substitutes). These 
kinetic characteristics suggest that the enzyme is active during ATP catabolism when AMP, 
ADP and inorganic phosphate concentrations rise. Inhibitors selective for cN-I over cN-II are 
dideoxynucleosides (particularly ddC and ddU) and these have been shown to decrease 
adenosine production from rat myocytes (10). This was the first direct evidence that cN-I 
could contribute to adenosine formation in cells. The role of cN-I was confirmed by plasmid 
based overexpression studies, which demonstrated the ability of cloned cN-IA to produce 
adenosine in established cell lines in the presence of inhibitors of adenosine metabolism (28, 
30).
Sequencing studies recently distinguished two isoforms of cN-I encoded by genes on 
human chromosomes 1 and 2, respectively. The form purified and kinetically characterized 
from pigeon heart and later used for protein sequencing and cloning was designated cN-IA 
(29). The kinetic properties of cN-IB have yet to be fully elucidated, although its basic 
characteristics in terms of Km, activation by AMP, insensitivity to inorganic phosphate and 
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inhibition by dideoxynucleosides appear similar to cN-IA. Moreover both isoforms can 
generate adenosine during ATP catabolism when overexpressed in COS-7 cells (29). Since 
cN-IA is abundantly expressed in hearts while cN-IB is poorly expressed in heart and 
predominant in testis we chose to focus on cN-IA in these experiments. Furthermore since the 
kinetic properties of purified and cloned cN-IA are highly conserved across species from 
pigeon to man (35, 36) we chose to overexpress the pigeon enzyme, for which we had 
suitable full-length clones.
The high Km for AMP of cN-I (~5mM) has cast doubts on its physiological function 
in myocardial adenosine formation because the predicted concentrations of free cytosolic 
AMP in cardiomyocytes are in the micromolar range. On the other hand, AMP deaminase 
also has a relative high Km for AMP ~0.6 mM that increases to ~2.4mM in the absence of 
ATP (20). Some cellular fractionation and histological evidence has implied that both cN-I 
and AMP deaminase may be associated with contractile fibres and therefore in a 
microenvironment exposed to higher AMP concentrations (27, 30). A further concern has 
been that any adenosine produced in the cytoplasm would have to escape metabolism by 
adenosine kinase and adenosine deaminase and be transported out through the equilibrative 
nucleoside transporter before it could activate extracellular adenosine receptors.  There 
remained doubts therefore whether cN-I could sufficiently elevate adenosine concentrations 
in primary cardiomyocytes in the face of adenosine metabolism to act at adenosine receptors. 
To investigate this question we first had to develop an adenovirus, which we showed capable 
of achieving high-level expression of cN-IA in primary cardiomyocytes. Our second goal was 
to measure adenosine formation and release during simulated hypoxia in the presence of 
inhibitors of adenosine metabolism. Although these experiments were not designed to 
measure initial rates of adenosine formation, we can calculate that 20 nmoles of adenosine 
were produced over 10 minutes in cN-IA transduced cells, which compares with the Vmax of 
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nearly 900 nmol.min-1.mg protein-1. Clearly the enzyme operates under far from saturating 
conditions, consistent with the low free cytosolic AMP concentrations.  Furthermore, by 
suppressing IMP, inosine and hypoxanthine concentrations, we showed that cN-IA 
effectively competed for substrate with AMP deaminase. Most importantly, we showed for 
the first time, that the enzyme was sufficiently active to elevate adenosine concentrations 
even in the absence of inhibitors of adenosine metabolism. 
All previous studies demonstrating adenosine formation from recombinant cN-I 
overexpression have used extreme conditions of ATP depletion. We showed here, however, 
that overexpression of cN-I provoked adenosine formation and elevated extracellular 
adenosine concentrations even under baseline conditions, when ATP levels were only 8% 
less than in β-galactosidase transduced cells.
Finally we sought to investigate whether cN-IA over expression could influence a 
response to adenosine mediated by extracellular adenosine receptors. Since neonatal 
myocytes are anchored to the substratum, cell shortening could not be quantified. Hence the 
most convenient parameter to measure was beating frequency. As previously shown (12), 
isoproterenol exerts a positive chronotropic effect on neonatal cardiomyocytes. This does not 
appear to be under tonic control by adenosine, because 8-SPT, a nonselective competitive 
inhibitor of adenosine receptors, had no stimulatory effect on the beating rate. However, 
added adenosine reversed the effect of isoproterenol, and this appeared to be receptor-
mediated. The partial effect of 8-SPT can be explained by the relatively high concentration of 
added adenosine used. Overexpression of cN-I produced a similar effect to added adenosine, 
which was in this case fully reversed by 8-SPT. The increase in adenosine formation and 
release by cN-IA overexpression persisted in the presence of isoproterenol and, from 
inhibitor experiments, was again independent of e-N but depended on nucleoside transport.  
The concentration of adenosine found in β-galactosidase transduced and cN-IA transduced 
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cardiomyocytes in the presence of isoproterenol ranged from 0.1-0.6 µM, which is in the 
range known to be effective at adenosine receptors (34). These results show, again for the 
first time, that cN-IA can generate sufficient concentrations of adenosine to exert 
physiological effects on cell surface receptors even in the face of adenosine metabolism. 
Limitations. While our overexpression studies demonstrate the potential of cN-IA to 
produce adenosine in cardiomyocytes, they clearly do not directly address the role of cN-IA 
in regulating myocardial adenosine concentrations and physiological actions in the heart. This 
will ultimately require transgenic and knockout experiments in mice for which our present 
experiments provide necessary justification.  The extracellular compartment in the intact 
myocardium is much smaller in proportion to that in isolated cardiomyocyte cultures and this 
would tend to potentiate the extracellular concentration of any adenosine formed in the 
cytoplasm and released from the nucleoside transporter. In this sense our experiments in 
isolated cardiomyocytes represent rather stringent conditions to test the role of cN- IA, which 
we compensated for by overexpressing the enzyme. A further limitation of our study is that 
we focused on the cardiomyocytes. Since endothelial cells also contribute to adenosine 
formation in the heart (6), future studies addressing the role of cN-I in those cells would also 
be valuable.
In conclusion, our studies demonstrate for the first time the activity of cloned cN-IA 
in primary rat cardiomyocytes. They demonstrate that cN-IA is sufficiently active to 
significantly increase adenosine concentration in the absence of inhibitors of adenosine 
metabolism and mediate physiological responses to adenosine at extracellular receptors.
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Table 1 Effect of cN-I overexpression and metabolic inhibitors on decreases in ATP 
concentration and cell viability
ATP decrease (% KRH control) LDH release (% total)
Treatment β-galactosidase cN-I β-galactosidase cN-I 
KRH 1.0±0.1 1.2±0.1
DOG 43±8 37±8 1.2±0.2 1.3±0.1
DOG+dithionite 56±15$ 54±12$ 1.2±0.1 1.1±0.1
DOG+cyanide 65±6† 71±6† 1.0±0.1 1.1±0.2
KRH+EHNA+5’NH2 1.1±0.2 1.1±0.3
DOG+EHNA+5’NH2 49±10 39±7 1.1±0.1 1.3±0.3
DOG+dithionite 
+EHNA+5’NH2
62±16$ 56±14$ 1.0±0.1 1.1±0.1
DOG+cyanide
+EHNA+5’NH2
71±8 75±7† 1.2±0.1 1.7±0.2 *
ATP concentrations measured by hplc are expressed as a percentage of the corresponding 
values obtained from β-galactosidase or cN-I transduced cells incubated in Kreb’s Ringer 
Hepes buffer (KRH) (47±2 versus 43±3 nmol ATP/mg protein, n=7, p<0.05) or 
KRH+EHNA+ 5’-amino-5’-deoxyadenosine (5’NH2) (48±3 vs 44±3 nmol ATP/mg protein, 
n=3, p=NS). LDH released into the medium is expressed as a percentage of the value in 
homogenates. Values are mean ± SEM of 3 separate experiments or otherwise stated. * 
p<0.05 versus β-galactosidase transduction. $ p<0.003 when all experiments with dithionite 
are compared to DOG alone. † p<0.01 for cyanide versus DOG alone, p<0.0001 when all 
experiments with cyanide are compared to DOG alone.
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